[PRNewswire] Altair to Showcase Pharmaceutical Process Optimization Technology

at the Korea Pharm&Bio 2023

-- Altair will feature pharmaceutical manufacturing process simulation and data analytics technologies

(SEONGNAM, South Korea, April 13, 2023 PRNewswire=연합뉴스) Altair [https://www.altair.com/ ] (Nasdaq: ALTR), a global leader in computational science and artificial intelligence (AI), will be exhibiting at Korea Pharm&Bio, April 18-21 in Goyang City, Gyeonggi-do, South Korea. At the event, Altair will showcase technologies and approaches that optimize pharmaceutical test analytics and manufacturing processes.

"We look forward to sharing our solutions that converge AI technology and simulation, a new paradigm for manufacturing bio, and further expand our business scope as a company specializing in AI," said Eunha Yu, Altair Korea branch manager.

On April 19, on the third floor of KINTEX, Altair engineer Mikyung Yang will present a talk on "Digital Twin of Pharmaceutical Process," where he will explain how to optimize pharmaceutical process and accumulated resources and leverage a data analysis platform that can utilize accumulated data.

As more than 75% of pharmaceuticals are powder formulations, Altair plans to expand its business in the Korean pharmaceutical market by highlighting the need for fine powder process optimization technology. At the event, Altair will share insight into Altair EDEM [https://www.altair.com/edem/ ], a particulate powder simulation widely used by global pharmaceutical companies.

In addition, data analytics solutions that utilize data and AI technology in the pharmaceutical bio industry will be introduced including Altair SLC [https://altair.com/altair-slc ] which runs programs written in SAS language syntax without translation and without needing to license third-party products. Altair SLC's built-in SAS language compiler runs SAS language and SQL code and utilizes Python and R compilers to run Python and R code and exchange SAS language datasets, Pandas, and R data frames. Altair RapidMiner [https://rapidminer.com/ ], Altair's data analytics and AI platform, will also be showcased, which includes massive data preparation, machine learning (ML), and visualization technologies.

AI technology is attracting attention as a technology that can reduce the cycle and cost of drug development, but it is difficult to secure a workforce with both an understanding of pharmaceutical manufacturing and AI technology capabilities. Altair's Center of Excellence [https://altair.com/newsroom/executive-insights/continuing-the-legacy-of-rapidminers-center-of-excellence ] (CoE) gives individuals, teams, and organizations the power to understand and implement data principles, tools, and approaches alongside Altair's experts. It is also a holistic, multi-faceted, continuous approach to learning and support that upskills anyone to the point where they can utilize basic data analysis and data science skills and techniques, even if they don't have a data background.

For more information, visit Altair booth #3G402 at Korea Pharm&Bio at KINTEX, April 18-21, or visit https://web.altair.com/pharmbio2023-0.

About Altair

Altair is a global leader in computational science and artificial intelligence (AI) that provides software and cloud solutions in simulation, high-performance computing (HPC), data analytics, and AI. Altair enables organizations across all industries to compete more effectively and drive smarter decisions in an increasingly connected world - all while creating a greener, more sustainable future. For more information, visit https://www.altair.com/.

Media contacts

Altair South Korea

Iseul Jeong

+82.10.7339.0740

iseul@altair.com

Altair Corporate

Jennifer Ristic

+1.216.849.3109

jristic@altair.com

Photo - https://mma.prnewswire.com/media/2052599/Altair_at_Korea_Pharm_Bio_2023.jpg

Altair to Showcase Pharmaceutical Process Optimization Technology at the Korea Pharm&Bio 2023

Logo - https://mma.prnewswire.com/media/1421069/Altair_Logo.jpg

Altair

Source: Altair

[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.

(끝)

출처 : PRNewswire 보도자료